NCT00434187
Completed
Phase 1
An Ascending Multiple Dose Study of the Safety, Tolerability and Pharmacokinetics of ERB-041 Administered Orally to Healthy, Female Japanese Subjects
Wyeth is now a wholly owned subsidiary of Pfizer0 sites24 target enrollmentAugust 2006
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Healthy
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Enrollment
- 24
- Primary Endpoint
- safety, pharmacokinetics
- Status
- Completed
- Last Updated
- 16 years ago
Overview
Brief Summary
The primary objective is evaluate the safety, tolerability, and pharmacokinetics of multiple doses of ERB-041, an investigational drug, in healthy, female Japanese subjects.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy as determined by the investigator on the basis of medical history and screening evaluations.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
safety, pharmacokinetics
Similar Trials
Completed
Phase 1
Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of MYO-029HealthyNCT00563810Wyeth is now a wholly owned subsidiary of Pfizer72
Terminated
Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsAlzheimer's DiseaseNCT02220738AbbVie19
Terminated
Phase 1
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)Type 2 Diabetes MellitusNCT01614782Merck Sharp & Dohme LLC24
Completed
Phase 1
Study Evaluating the Pharmacokinetics of HCV-796 in Healthy Japanese MenHealthyNCT00385190Wyeth is now a wholly owned subsidiary of Pfizer24
Completed
Phase 1
A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)SchizophreniaNCT05406440Merck Sharp & Dohme LLC53